公开(公告)号：US20100273793A1

公开(公告)日：2010-10-28

申请号：US12761973

申请日：2010-04-16

Applicant: Conception Nemecek ,  Sylvie Wentzler

Inventor： Conception Nemecek ,  Sylvie Wentzler

IPC: A61K31/5377 ,  C12N9/99 ,  A61K31/428 ,  A61K31/4184 ,  C07D417/02 ,  C07D413/02 ,  C07D277/82 ,  C07D235/30 ,  A61P3/10 ,  A61P35/00 ,  A61P3/00 ,  A61P17/06

CPC classification number: C07D235/30 ,  C07D235/32 ,  C07D277/82 ,  C07D417/12

Abstract: The disclosure relates to compounds of formula (I): wherein A, W, R, R5, and R6 are as defined in the disclosure, or a salt thereof, and to their use as drugs, in particular as c-Met inhibitors.

Abstract translation: 本公开涉及式（I）的化合物：其中A，W，R，R 5和R 6如本公开内容中所定义，或其盐，以及其作为药物，特别是作为c-Met抑制剂的用途。

公开(公告)号：US07786114B2

公开(公告)日：2010-08-31

申请号：US11692321

申请日：2007-03-28

Applicant: Conception Nemecek ,  William A. Metz ,  Sylvie Wentzler ,  Dominique Lesuisse ,  Youssef El-Ahmad

Inventor： Conception Nemecek ,  William A. Metz ,  Sylvie Wentzler ,  Dominique Lesuisse ,  Youssef El-Ahmad

IPC: A61K31/535 ,  A61K31/44 ,  A61K31/497 ,  C07D401/00 ,  C07D413/00

CPC classification number: C07D519/00

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.

Abstract translation: 式（I）化合物：其中R1，R2，R3，R4和R5具有说明书中给出的含义及其盐，包含所述化合物的药物组合物及其作为蛋白激酶抑制剂的用途。

公开(公告)号：US07528147B2

公开(公告)日：2009-05-05

申请号：US11541051

申请日：2006-09-29

Applicant: Sylvie Wentzler ,  Youssef El-Ahmad ,  Bruno Filoche-Rommé ,  Conception Nemecek ,  Corinne Venot ,  Augustin Hittinger

Inventor： Sylvie Wentzler ,  Youssef El-Ahmad ,  Bruno Filoche-Rommé ,  Conception Nemecek ,  Corinne Venot ,  Augustin Hittinger

IPC: A01N43/42 ,  A61K31/44 ,  C07D471/02 ,  C07D491/02 ,  C07D498/02 ,  C07D513/02 ,  C07D515/02

CPC classification number: C07D471/04

Abstract: Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.

Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，其中R，R 1，R 2，R 3，R 4，R 5和R 6具有说明书中给出的含义，包含所述化合物的药物组合物及其作为蛋白激酶抑制剂的用途。

公开(公告)号：US20080194555A1

公开(公告)日：2008-08-14

申请号：US12054719

申请日：2008-03-25

Applicant: Conception NEMECEK ,  Francois CLERC

Inventor： Conception NEMECEK ,  Francois CLERC

IPC: A61K31/5377 ,  C07D235/30 ,  C07D417/12 ,  A61K31/4184

CPC classification number: C07D235/30 ,  C07D277/82

Abstract: This invention relates to benzimidazole and benzothiazole compounds of formula (I) to methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.

Abstract translation: 本发明涉及式（I）的苯并咪唑和苯并噻唑化合物与制备这些化合物的方法，包含这些化合物的药物组合物以及包括给予这些化合物的治疗方法。

公开(公告)号：US20080108654A1

公开(公告)日：2008-05-08

申请号：US11972314

申请日：2008-01-10

Applicant: Marcel PATEK ,  Anil NAIR ,  Augustin HITTINGER ,  Conception NEMECEK ,  Daniel BOND ,  Greg HARLOW ,  Herve BOUCHARD ,  Jacques MAUGER ,  Jean-Luc MALLERON ,  Mark PALERMO ,  Fahad AL-OBEIDI ,  Thomas FAITG ,  Hartmut STROBEL ,  Sven RUF ,  Kurt RITTER ,  Youssef EL-AHMAD ,  Dominique LESUISSE

Inventor： Marcel PATEK ,  Anil NAIR ,  Augustin HITTINGER ,  Conception NEMECEK ,  Daniel BOND ,  Greg HARLOW ,  Herve BOUCHARD ,  Jacques MAUGER ,  Jean-Luc MALLERON ,  Mark PALERMO ,  Fahad AL-OBEIDI ,  Thomas FAITG ,  Hartmut STROBEL ,  Sven RUF ,  Kurt RITTER ,  Youssef EL-AHMAD ,  Dominique LESUISSE

IPC: A61K31/47 ,  C07D401/02 ,  C07D401/14 ,  A61K31/444 ,  A61P11/06 ,  A61P25/00 ,  A61P35/00 ,  C12N9/99 ,  A61K31/4439

CPC classification number: C07D401/06 ,  C07D401/14

Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

Abstract translation: 本公开涉及式I的环脲化合物：如本文所定义，其制备方法，包含其的药物组合物及其作为蛋白激酶上的抑制剂的药物用途。 因此，式I化合物可用于预防或治疗能够通过抑制蛋白激酶如实体瘤的活性而被调节的生理障碍。

公开(公告)号：US20050009831A1

公开(公告)日：2005-01-13

申请号：US10803566

申请日：2004-03-18

Applicant: Andrew Ratcliffe ,  Roger Aitchison Walsh ,  Tahir Majid ,  Sukanthini Thurairatnam ,  Shelley Amendola ,  David Aldous ,  John Souness ,  Conception Nemecek ,  Sylvie Wentzler ,  Corinne Venot

Inventor： Andrew Ratcliffe ,  Roger Aitchison Walsh ,  Tahir Majid ,  Sukanthini Thurairatnam ,  Shelley Amendola ,  David Aldous ,  John Souness ,  Conception Nemecek ,  Sylvie Wentzler ,  Corinne Venot

IPC: A61K31/495 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C07D487/04

CPC classification number: A61K31/495 ,  C07D487/04 ,  Y02A50/411

Abstract: The present invention concerns compounds of general formula (I): in which: R1 represents hydrogen, R4, —C(═Y)—NHR4, —SO2NHR4, —C(=Z1)—R4, —SO2—R4 or —C(=Z1)—OR4; R2 represents hydrogen, cyano, halogen or —C≡C—R5; R3 represents hydrogen, acyl, alkoxycarbonyl, alkyl, aroyl, aryl, aryloxycarbonyl, carboxy, cycloalkenyl, cycloalkyl, heteroaroyl, heteroaryl, heterocycloalkyl or —C(═O)—NY1Y2; R4 represents optionally substituted alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl R5 represents hydrogen or alkyl; R6 represents alkyl, acyl, alkoxycarbonyl, alkylsulfonyl, aryl, arylsulfonyl, aroyl, cycloalkyl, cycloalkenyl, heteroaryl, heteroarylsulfonyl, heteroaroyl and heterocycloalkyl; R7 represents optionally substituted alkyl, cycloalkyl or cycloalkylalkyl, R8 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R9 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R10 represents hydrogen or lower alkyl; R11 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; or alkyl optionally substituted by —NY1Y2; R12 represents aryl or heteroaryl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted Y represents O, S or NCN; Y1 and Y2 (Y3 and Y4) are independently in particular hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocycloalkyl; or the group —NY1Y2 may form 5-7 membered ring or the group —NY3Y4 (—NY5Y6) may form a cyclic amine; Z (Z1) represents O or S; Z2 represents O or S(O)p; n is zero or an integer 1 or 2; m is 1 or 2; p is 1 or 2; and their corresponding N-oxides, their prodrugs; their pharmaceutically acceptable salts and solvates (e.g. hydrates), also together with one or more pharmaceutically acceptable carriers or excipients, such novel indolizines derivatives with inhibitory effects towards kinase proteins and especially for use for preventing or treating diseases that may be modulated by the inhibition of such kinase proteins and particularly solid tumours.

公开(公告)号：US06194426B1

公开(公告)日：2001-02-27

申请号：US08981095

申请日：1997-12-12

Applicant: Eric Bacque ,  Conception Nemecek ,  Georges Bashiardes ,  Norbert Dereu

Inventor： Eric Bacque ,  Conception Nemecek ,  Georges Bashiardes ,  Norbert Dereu

IPC: A61K31437

CPC classification number: C07D471/04 ,  A61K31/4439 ,  C07D487/04 ,  C07D513/04

Abstract: A novel therapeutic use of pyrrole derivatives of the folloeing formula: in which the variables are as defined in the specification and their salts thereof for treating conditions in which TNF is involved.

Abstract translation: 下列配方的吡咯衍生物的新型治疗用途：其中变量如本说明书及其盐中所定义，用于治疗涉及TNF的病症。